Literature DB >> 15134798

Primary aldosteronism--careful investigation is essential and rewarding.

Michael Stowasser1, Richard D Gordon.   

Abstract

Once considered rare, primary aldosteronism (PAL) is now regarded as the commonest potentially curable and specifically treatable form of hypertension. At Greenslopes Hospital Hypertension Unit (GHHU), the decision in 1991 to screen all (and not just hypokalemic or resistant) hypertensives by aldosterone/renin ratio (ARR) testing led to a 10-fold increase in detection rate of PAL and four-fold increase in removal rate of aldosterone-producing adenomas (APAs). The GHHU/Princess Alexandra Hospital Hypertension Unit PAL series stands at 977 patients and 250 APAs removed with hypertension cured in 50-60% (remainder improved). Reliable detection requires that interfering medications are withdrawn (or their effects considered) before ARR measurement, and reliable methods (such as fludrocortisone suppression testing) to confirm PAL. Adrenal venous sampling is the only dependable way to differentiate APA from bilateral adrenal hyperplasia. Genetic testing has facilitated detection of glucocorticoid-remediable, familial PAL. Identification of mutations causing the more common familial variety described by GHHU in 1991 should further aid in detection of PAL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15134798     DOI: 10.1016/j.mce.2003.10.006

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  30 in total

1.  Laboratory investigation of primary aldosteronism.

Authors:  Michael Stowasser; Paul J Taylor; Eduardo Pimenta; Ashraf H Al-Asaly Ahmed; Richard D Gordon
Journal:  Clin Biochem Rev       Date:  2010-05

2.  Potential effects of age on screening for primary aldosteronism.

Authors:  Q Luo; N F Li; X G Yao; D L Zhang; S F Y Abulikemu; G J Chang; K M Zhou; G L Wang; M H Wang; W J Ouyang; Q Y Cheng; Y Jia
Journal:  J Hum Hypertens       Date:  2015-04-16       Impact factor: 3.012

3.  Different expression of 11β-hydroxylase and aldosterone synthase between aldosterone-producing microadenomas and macroadenomas.

Authors:  Yoshikiyo Ono; Yasuhiro Nakamura; Takashi Maekawa; Saulo J A Felizola; Ryo Morimoto; Yoshitsugu Iwakura; Masataka Kudo; Kazumasa Seiji; Kei Takase; Yoichi Arai; Celso E Gomez-Sanchez; Sadayoshi Ito; Hironobu Sasano; Fumitoshi Satoh
Journal:  Hypertension       Date:  2014-05-19       Impact factor: 10.190

4.  Significance of adrenal computed tomography in predicting laterality and indicating adrenal vein sampling in primary aldosteronism.

Authors:  K Kamemura; N Wada; T Ichijo; Y Matsuda; Y Fujii; T Kai; T Fukuoka; R Sakamoto; A Ogo; T Suzuki; H Umakoshi; M Tsuiki; M Naruse
Journal:  J Hum Hypertens       Date:  2016-09-01       Impact factor: 3.012

Review 5.  Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment.

Authors:  Gregory L Hundemer
Journal:  Curr Cardiol Rep       Date:  2019-07-27       Impact factor: 2.931

Review 6.  Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism.

Authors:  Laurence Amar; Pierre-François Plouin; Olivier Steichen
Journal:  Orphanet J Rare Dis       Date:  2010-05-19       Impact factor: 4.123

Review 7.  Resistant Hypertension Updated Guidelines.

Authors:  Irene Chernova; Namrata Krishnan
Journal:  Curr Cardiol Rep       Date:  2019-08-30       Impact factor: 2.931

Review 8.  Progress in primary aldosteronism: present challenges and perspectives.

Authors:  C E Gomez-Sanchez; G P Rossi; F Fallo; M Mannelli
Journal:  Horm Metab Res       Date:  2010-01-20       Impact factor: 2.936

Review 9.  Heritable forms of hypertension.

Authors:  V Matti Vehaskari
Journal:  Pediatr Nephrol       Date:  2007-07-24       Impact factor: 3.714

10.  Adrenal venous sampling: where is the aldosterone disappearing to?

Authors:  Miroslav Solar; Jiri Ceral; Antonin Krajina; Marek Ballon; Eva Malirova; Milos Brodak; Jan Cap
Journal:  Cardiovasc Intervent Radiol       Date:  2009-10-01       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.